FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma.
Ladányi
Andrea
A
Center of Surgical and Molecular Tumor Pathology, National Institute of Oncology, 7-9 Ráth György u., Budapest, Hungary. ladanyi@oncol.hu
Mohos
Anita
A
Somlai
Beáta
B
Liszkay
Gabriella
G
Gilde
Katalin
K
Fejos
Zsuzsanna
Z
Gaudi
István
I
Tímár
József
J
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis / Q000276:immunology*; D005260:Female; D051858:Forkhead Transcription Factors / Q000096:biosynthesis / Q000276:immunology*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012878:Skin Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000378:metabolism
D014408:Biomarkers, Tumor; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors